BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 24053128)

  • 1. Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia.
    Ranasinghe WK; Kim SP; Lawrentschuk N; Sengupta S; Hounsome L; Barber J; Jones R; Davis P; Bolton D; Persad R
    BJU Int; 2014 Jan; 113(1):77-83. PubMed ID: 24053128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
    Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK
    Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison between 2 techniques of screening for prostatic carcinoma. Rectal exploration and transrectal ultrasonography vs. prostate specific antigen].
    Ciatto S; Bonardi R; Mazzotta A; Lombardi C; Santoni R; Cardini S; Zappa M
    Radiol Med; 1994 Oct; 88(4):453-7. PubMed ID: 7527916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
    Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
    BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
    Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
    J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
    Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR
    Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between literacy, compliance with prostate cancer screening, and cancer aggressiveness: results from a Brazilian screening study.
    Tobias-Machado M; Carvalhal GF; Freitas CH; Reis RB; Reis LO; Nogueira L; Machado RD; Magnabosco W; Vieira RA; Mauad EC; Carvalho AL; Faria EF;
    Int Braz J Urol; 2013; 39(3):328-34. PubMed ID: 23849582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
    Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mass screening of 12,027 elderly men for prostate carcinoma by measuring serum prostate specific antigen.
    Zhang HF; Wang HL; Xu N; Li SW; Ji GY; Li XM; Pan YZ; Zhang L; Zhao XJ; Gao HW
    Chin Med J (Engl); 2004 Jan; 117(1):67-70. PubMed ID: 14733776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound-guided template saturation biopsy.
    Mabjeesh NJ; Lidawi G; Chen J; German L; Matzkin H
    BJU Int; 2012 Oct; 110(7):993-7. PubMed ID: 22394668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project.
    Pelzer AE; Tewari A; Bektic J; Berger AP; Frauscher F; Bartsch G; Horninger W
    Urology; 2005 Nov; 66(5):1029-33. PubMed ID: 16286118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
    Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of prostate-specific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of ≤10 ng/mL.
    Hong SK; Oh JJ; Byun SS; Hwang SI; Choo MS; Lee SE
    BJU Int; 2012 Jul; 110(2 Pt 2):E81-5. PubMed ID: 22093144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
    Men S; Cakar B; Conkbayir I; Hekimoglu B
    J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transperineal template prostate biopsies in men with raised PSA despite two previous sets of negative TRUS-guided prostate biopsies.
    Nafie S; Pal RP; Dormer JP; Khan MA
    World J Urol; 2014 Aug; 32(4):971-5. PubMed ID: 24337167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.